These results are consistent with the CNS-protective effects of alectinib as described previously in patients with ALK-positive NSCLC; in the ALEX study, the time to CNS progression was significantly longer with alectinib versus crizotinib (cause-specific HR = 0.16, 95% CI: 0.10–0.28, p < 0.001); 12% (18 of 152) of alectinib-treated patients and 45% (68 of 151) of crizotinib-treated patients had a CNS progression event) demonstrating that treatment with alectinib reduces the risk of CNS progression in patients with ALK-positive NSCLC.11 The gene discussed is ALK; the disease is non-small cell lung carcinoma.